We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.

Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr ...

Genomics (NasdaqGS:TXG) is collaborating with PerturbAI, NVIDIA, and the Allen Institute on what is described as the largest in vivo CRISPR brain atlas. The partnership combines 10x Genomics' single ...

Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the future of gene editing.

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Current shareholders were thrown an unexpected curveball that they actually should have been expecting.

After a heart attack, the heart struggles to recoup and maintain energy. One-third of patients develop heart failure as a ...

CRISPR Therapeutics recently reported that rollout of its approved gene therapy Casgevy for sickle cell disease and transfusion‑dependent beta thalassemia has been slower than hoped, contributing to a ...

A silent revolution is unfolding inside Indian laboratories. From the patent-free power of an indigenous CRISPR tool to ...

CRISPR Therapeutics (CRSP) is back in focus after upsizing its convertible note offering to US$550 million, a key funding move tied directly to the company’s gene editing ambitions and CASGEVY ...